ELAHEH KHALEDIZADEH

Dr. ELAHEH KHALEDIZADEH

Experimental Medicine, Unige, Genoa, Liguria, Italy
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2023 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
ELAHEH KHALEDIZADEHELAHEH KHALEDIZADEH
ELAHEH KHALEDIZADEH
FTFarzaneh Tafvizi
Farzaneh Tafvizi
PJParvaneh Jafari
Parvaneh Jafari

Verified
Journal Article
Open access
PDF file
Silvana AlfeiSilvana Alfei
Silvana Alfei
CTCarola Torazza
Carola Torazza
Francesca BacchettiFrancesca Bacchetti
Francesca Bacchetti
Marco MilaneseMarco Milanese
Marco Milanese
MPMario Passalacqua
Mario Passalacqua
Barbara MarengoBarbara Marengo
Barbara Marengo
Neuroblastoma (NB) is a malignant childhood tumour, which originates from neuroblasts with an incidence of approximately 15,000 new cases per year worldwide. Therapy-induced secondary tumorigenesis and the emergency of drug resistance in its high-risk (HR-NB) forms drive to a survival rate of <50%, despite aggressive treatments. Our recent research is focused on testing in vitro the effects of synthetized triphenyl phosphonium (TPP)-based bola amphiphilic nanovesicles (BPPBs) against both drug-sensitive and multi-drug-resistant (MDR) cancer cell lines. In the present study, BPPB demonstrated sub-micromolar IC50 values (0.4–0.9 µM) towards drug-sensitive HTLA 230, while 1.20–1.35 µM IC50 were determined on MDR HTLA ER. Noteworthily, we have demonstrated that BPPB triggers apoptosis of both NB cell populations. Additionally, since MDR NB cells (HTLA ER) are equipped with higher levels of antioxidants than sensitive ones (HTLA 230), the potential involvement of reactive oxygen species (ROS) in the cytotoxic action of BPPB was also investigated. Then, a novel analytical approach was applied to the results of cell viability and ROS monitoring for their better interpretation. Proper dispersion graphs and their best fitting nonlinear regression models were used to verify if the cytotoxic effects of BPPB could depend on BPPB concentrations, exposure times, and/or ROS generation, and if ROS increase could depend on BPPB concentrations and/or exposure times. A ROS-dependent mechanism was found in 24 h and 24/48 h treatments of HTLA ER and HTLA 230, respectively. Furthermore, the potential clinical development of BPPB as a new curative option for children affected by HR-NB was assessed by testing BPPB on astrocyte and neuron primary cell cultures, and analytical correlation studies were used to interpret the results. Notably, BPPB administration was sufficiently and well tolerated by neurons and astrocytes, respectively, allowing selectivity index values of up to 23.7. These in vitro results, associated with the low haemolytic activity of BPPB, pave the way for future in vivo investigations and, upon confirmation, for the possible development of BPPB as a novel therapeutic strategy to treat MDR HR-NB.

Verified
Journal Article
Open access
PDF file
Silvana AlfeiSilvana Alfei
Silvana Alfei
MSMaria Grazia SIGNORELLO
Maria Grazia SIGNORELLO
STSara Tirendi
Sara Tirendi
ELAHEH KHALEDIZADEHELAHEH KHALEDIZADEH
ELAHEH KHALEDIZADEH
Paolo GiordaniPaolo Giordani
Paolo Giordani
Cinzia DomenicottiCinzia Domenicotti
Cinzia Domenicotti
Late-stage metastatic cutaneous melanoma (MCM) and neuroblastoma (NB) are the most aggressive skin and childhood cancers with survival rates of <50%, mainly due to the emergence of resistance to available drugs, thus requiring an urgent solution. Quaternary phosphonium salts (QPSs) can exhibit strong anticancer effects, regardless of the developed resistance. Triphenyl (1) and diphenyl (3 and 4) phosphonium salts were synthesized, treating commercial triphenyl phosphine and synthesizing 11-diphenylphosphanyl-undecan-1-ol (2), respectively, with benzyl bromide. Upon full characterization, they were tested, for the first time, on MeTRAV (BRAFV600D) and MeOV (BRAFV600E) vemurafenib (PLX)-resistant MCM cells, etoposide (ETO)-sensitive (HTLA 230) and multidrug resistant (MDR) (HTLA ER) NB cells, non-tumorigenic human keratinocytes (HaCaT), and mouse embryonic fibroblasts (3T3), as well as red blood cells (RBCs). Viability of MeTRAV cells was decreased to 44.8% by administration of 1 (100 µM), in intermediate-time (48 h) treatments, while short-time exposure (24 h) to 3 (≥75 µM) and 4 (≥50 µM) was sufficient to reduce their viability to 33.6 and 32.2%. Viability of MeOV was decreased under 50% with 5 µM concentrations of 1 and 25 µM of 3 and 4, While cells were exterminated (26.9, 20.6, and 21.8%) with higher concentrations after 48 h exposure. Collectively, 1 was the better performing compound (IC50 = 6.4 µM, 48 h). Viability of HTLA ER cells was decreased under 50% upon 72 h administrations of 1 at concentrations ≥ 50 µM, 48 h (≥75 µM) and 72 h (≥50 µM) of 3, and after 72 h (≥75 µM) of 4, but 72 h exposure and high concentrations of all compounds were necessary for their extermination (31.2, 28.7, and 29.7%). Viability of HTLA 230 cells was not <50% when 1 and 4 were administered for only 24 h, while their viability was <50% after administration of 3 at all times of exposure. At high concentrations, all compounds exterminated cells (33.6, 25.3%, 1, 48–72 h; 38.6, 30.2, and 24.7%, 3, 24–72 h; 33.2%, 4, 72 h). The best-performing compounds were 1 (IC50 = 4.0 µM, HTLA 230) and 3 (IC50 = 27.8 µM, HTLA ER) at 72 h exposure. The cytotoxic effects of compound 4 on MeTRAV cells, when exposed to 24/48 h treatments, were comparable to those of PLX on the same cells in 72 h treatments. Compound 1, in shorter 48 h treatments of PLX-R MeOV, was 2.5-fold more cytotoxic than PLX in 72 h ones. All compounds were not cytotoxic to 3T3 cells at all times of exposure; they had low cytotoxicity to HaCaT cells in 24 and 48 h treatments and were slightly cytotoxic to RBCs in 24 h ones. Compound 1 could be a promising platform to develop new intermediate-time therapies for PLX-R MeOV cells, while 4 could be used to develop 24 and 48 h treatments for PLX-R MeTRAV cells. Also, all compounds could be developed as new treatment options for both ETO-sensitive and MDR late-stage HR-NB cells, being even more effective than ETO by 1.2, 2.0, and 1.3 times (HTLA 230) and 3.2, 4.7, and 3.2 times (HTLA ER). All compounds have the potential to be developed as adjuvants in already existing anticancer cocktails to treat MCM and/or NB.

10 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Silvana AlfeiSilvana Alfei
Silvana Alfei
MSMaria Grazia SIGNORELLO
Maria Grazia SIGNORELLO
STSara Tirendi
Sara Tirendi
ELAHEH KHALEDIZADEHELAHEH KHALEDIZADEH
ELAHEH KHALEDIZADEH
Paolo GiordaniPaolo Giordani
Paolo Giordani
Cinzia DomenicottiCinzia Domenicotti
Cinzia Domenicotti
Background. Late-stage metastatic cutaneous melanoma (MCM) and neuroblastoma (NB) are the most aggressive skin and childhood cancers with survival rate < 50%, mainly due to the emergence of resistance to available drugs, thus requiring urgent solution. Quaternary phosphonium salts (QPSs) can exhibit up to strong anticancer effects, regardless the developed resistances. Methods. Triphenyl (1) and diphenyl (3 and 4) phosphonium salts were synthesized, treating commercial triphenyl phosphine and synthesized 11-diphenylphosphanyl-undecan-1-ol (2) respectively, with benzyl bromide. Upon fully characterization, they were tested, for the first time, on MeTRAV (BRAFV600D) and MeOV (BRAFV600E) vemurafenib (PLX)-resistant MCM cells, etoposide (ETO)-sensitive (HTLA 230) and multidrug resistant (MDR) (HTLA ER) NB cells, not tumorigenic human keratinocytes (HaCaT) and mouse embryonic fibroblasts (3T3), as well as red blood cells (RBCs). Results and Discussion. Viability of MeTRAV cells was decreased to 44.8% by admin-istration of 1 (100 µM), in intermediate-time (48h) treatments, while short-time exposure (24h) to 3 (≥ 75 µM) and 4 (≥ 50 µM) was sufficient to reduce their viability to 33.6 and 32.2%. Viability of MeOV was decreased under 50% with 5 µM concentrations of 1 and 25 µM of 3 and 4, while were exterminated (26.9, 20.6 and 21.8%) with higher concentrations after 48h exposure. Collectively, 1 was the better performant compound (IC50 = 6.4 µM, 48h). Viability of HTLA ER cells was decreased under 50% upon 72h administrations of 1 at concentrations ≥ 50 µM, 48h (≥ 75 µM) and 72h (≥ 50 µM) of 3 and after 72h (≥ 75 µM) of 4, but 72-hours exposure and high concentrations of all compounds were necessary for their extermination (31.2, 28.7, 29.7%). Viability of HTLA 230 cells was not < 50% when 1 and 4 were administered for only 24h, while their viability was < 50% after administration of 3 at all-times exposure. At high concentrations all compounds exterminated cells (33.6, 25.3%, 1, 48-72h; 38.6, 30.2, 24.7%, 3, 24-72h; 33.2%, 4, 72h). The best performant compounds were 1 (IC50 = 4.0 µM, HTLA 230) and 3 (IC50 = 27.8 µM, HTLA ER) at 72h exposure. The cytotoxic effects of compound 4 on MeTRAV cells, when exposed to 24/48h treatments were comparable to those of PLX on same cells in 72h ones. 1, in shorter 48h treatments of PLX-R MeOV, was 2.5forl more cytotoxic than PLX in 72h ones. All compounds were no cytotoxic to 3T3 cells, at all time of exposure, low cytotoxic to HaCaT cells in 24 and 48h treatments and softly cytotoxic to RBCs in 24h ones. Conclusions. Compound 1 could be a promising platform to develop new intermediate-time therapies for PLX-R MeOV cells, while 4, to develop 24- and 48-hours treatments for PLX-R MeTRAV cells. Also, all compounds could be developed as new treatment options for both ETO-sensitive and MDR late-stage HR-NB cells, being all more effective than ETO by 1.2, 2.0, 1.3 times (HTLA 230) and 3.2, 4.7 and 3.2 times (HTLA ER). All compounds could be interesting to be developed as adjuvants in already existing anticancer cocktails to treat MCM and/or NB.

Verified
Journal Article
Open access
PDF file
Silvana AlfeiSilvana Alfei
Silvana Alfei
Cinzia DomenicottiCinzia Domenicotti
Cinzia Domenicotti
STSara Tirendi
Sara Tirendi
ELAHEH KHALEDIZADEHELAHEH KHALEDIZADEH
ELAHEH KHALEDIZADEH
DGDafni G Graikioti
Dafni G Graikioti
Barbara MarengoBarbara Marengo
Barbara Marengo
High-risk neuroblastoma (HR-NB) remains a major clinical challenge due to the emergence of therapy resistance. In this study, the anticancer effects of seven previously synthesized betulin (BET), betulinic acid (BA) and ursolic acid (UA) derivatives (1–7) and of their natural precursors BET, BA and UA (8–10) were investigated in HTLA NB cells, selected as the experimental model by MTT assay, to find a possible solution to drugs that have lost their effect. Dynamic light scattering (DLS) analysis showed that amphiphilic compounds 1 and 4–7 form nanovesicles (240–448 nm) in water, while all compounds have high positive ζ-potential (ζ-p, +28.5–+83.1 mV), supporting favourable membrane interaction and cellular uptake. Cytotoxic experiment results and related IC50 values were expressed as the mean ± SD of four independent experiments run in triplicate. Most derivatives exhibited a cytotoxic activity higher than that of their natural precursors and outperformed etoposide; they were particularly effective against the multidrug resistant (MDR) HTLA ER cells. Among them, the ursolic acid (UA) derivative 7 emerged as the most active compound, displaying sub-micromolar to low micromolar IC50 values and markedly improving the activity of native UA. Functional studies revealed that it induces complete suppression of clonogenic growth at low micromolar concentrations in both HTLA ER and parental HTLA 230 NB cells. In addition, a concentration-dependent downregulation of Akt, p-Akt, BMI1 and PARP, was observed consistently with a marked suppression of survival pathways and loss of cellular homeostasis. Collectively, our experiments, which need further direct investigation to confirm subsequent assumption, could suggest that compound 7 could kill cancer cells via a non-apoptotic, bioenergetic collapse mechanism. All of these findings suggest compound 7 as a promising mitochondria-targeted lead candidate and support amphiphilic triterpenoid derivatives as attractive platforms for overcoming multidrug resistance in high-risk NB.